-
Sector Analysis
Parkinson’s Disease Epidemiology Analysis and Forecast to 2033
Parkinson’s Disease Report Overview In the 7MM, there were 2,636,930 diagnosed prevalent cases of Parkinson’s Disease in 2023. The market will register an AGR of more than 1% during 2023-2033. This increase in the cases of PD across the 7MM is primarily attributed to changes in the underlying population demographics. Parkinson’s disease (PD) is an incurable neurodegenerative disease clinically categorized as a movement disorder with prominent motor symptoms, including tremors, rigidity, and bradykinesia. The clinical presentation of PD is characterized...
-
Product Insights
Idiopathic Hypersomnia (IH) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Idiopathic Hypersomnia (IH) Clinical Trial Report Overview A total of 42 idiopathic hypersomnia (IH) clinical trials were conducted as of October 2024. The idiopathic hypersomnia (IH) clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      Asia-Pacific ·      ...
-
Sector Analysis
Multiple System Atrophy (MSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Multiple System Atrophy (MSA) Marketed and Pipeline Drugs Report Overview MSA is a rare, sporadic, progressive neurological disorder characterized by various symptoms and signs. There is about one living case of MSA in the population for every 40 cases of Parkinson’s disease (PD). However, survival in MSA is shorter than for PD, with about one new MSA case diagnosed each year for every 20 new PD cases. The MSA marketed and pipeline drugs market research report includes an assessment of...
-
Product Insights
Delirium Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Delirium Clinical Trial Report Overview A total of 964 delirium clinical trials were conducted as of August 2024. The delirium clinical trial report provides a comprehensive understanding of the delirium clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      Asia-Pacific ·      North America ·      Europe ·      ...
-
Product Insights
Metachromatic Leukodystrophy (MLD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Metachromatic Leukodystrophy (MLD) - Global Clinical Trials Review, 2024" provides an overview of Metachromatic Leukodystrophy (MLD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Metachromatic Leukodystrophy (MLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Camrelizumab...
-
Sector Analysis
Frontotemporal Dementia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Frontotemporal Dementia therapeutics. • In 2024, more than 700,000 diagnosed prevalent cases of FTD are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for FTD. • There are currently no approved therapies for FTD in the market. • The FTD pipeline is notably sparse, with no assets in the pre-registration stage, a single asset in Phase III development. • Over the past 10 years,...
-
Product Insights
Spinal Muscular Atrophy (SMA) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Spinal Muscular Atrophy (SMA) Clinical Trial Report Overview A total of 230 spinal muscular atrophy (SMA) clinical trials have been conducted as of July 2024. The spinal muscular atrophy (SMA) clinical trial report provides a comprehensive understanding of the spinal muscular atrophy (SMA) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium (186Re) Obisbemeda in Leptomeningeal...
-
Product Insights
Huntington Disease - Drugs In Development, 2024
Empower your strategies with our Huntington Disease – Drugs In Development, 2024 report and make more profitable business decisions. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.